Table 3.

Relative treatment effect comparisons (95% CI) for cardiovascular death (upper triangle) and all-cause mortality (lower triangle).

Standard of care	0.89 (0.62, 1.27)	0.95 (0.71, 1.27)	0.92 (0.78, 1.09)	0.88 (0.74, 1.06)	0.78 (0.57, 1.06)
0.86 (0.63, 1.18)	Sotagliflozin	1.07 (0.67, 1.69)	1.04 (0.70, 1.54)	0.99 (0.66, 1.49)	0.87 (0.55, 1.40)
0.97 (0.75, 1.25)	1.12 (0.75, 1.67)	Ertugliflozin	0.98 (0.70, 1.36)	0.93 (0.66, 1.31)	0.82 (0.54, 1.25)
1.01 (0.86, 1.17)	1.17 (0.82, 1.65)	1.04 (0.77, 1.40)	Empagliflozin	0.96 (0.75, 1.22)	0.84 (0.59, 1.19)
0.84* (0.72, 0.98)	0.97 (0.69, 1.38)	0.87 (0.64, 1.17)	0.83 (0.67, 1.04)	Dapagliflozin	0.88 (0.62, 1.26)
0.76 (0.58, 1.00)	0.88 (0.58, 1.33)	0.78 (0.54, 1.14)	0.75 (0.55, 1.03)	0.90 (0.66, 1.24)	Canagliflozin

Comparison should be read from right to left. In the upper rectangle, a relative risk of <1 favors the drug in the column. In the lower rectangle, a relative risk of <1 favors the drug in the row.

*Statistical significance.